pentobarbital will minimize the level or impact of roflumilast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not recommended; potent cytochrome P450 enzyme inducers minimize systemic publicity to roflumilast and will decrease the therapeutic usefulnesspentobarbital will lower the extent or effect of ond